RxDoctor Payments Data

Lillian Moy-Yee, MD

Internal Medicine · Wilmington, MANPI 1730162181

Payments from drug & device makers

$1,318in general payments, 2019–2025

Across 72 payments — averaging $18.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$253
  • Boehringer Ingelheim$250
  • Lilly USA, LLC$160
  • Amgen$107
  • Johnson & Johnson$81
  • Novo Nordisk$81
  • plus $386 from 9 others

What the payments were for

  • Food & beverage$1,318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,318 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$133,759
Medicare patients
311
Services billed
1,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$74,904
JardianceEmpagliflozin26$38,660
TrulicityDulaglutide20$21,168
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$15,525
Rosuvastatin Calcium239$6,089
Repatha SyringeEvolocumab11$5,373
MyrbetriqMirabegron11$4,901
Atorvastatin Calcium403$4,738
Olmesartan Medoxomil95$3,430
Metoprolol Succinate152$2,374
Lisinopril348$2,128
Ezetimibe34$1,874
Simvastatin179$1,782
Wixela InhubFluticasone Propion/Salmeterol14$1,671
Albuterol Sulfate HfaAlbuterol Sulfate48$1,642

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$253$74,90466 claims
Boehringer IngelheimJardiance$250$38,66026 claims
Lilly USA, LLCTrulicity$160$21,16820 claims
GSKTrelegy Ellipta$40$15,52512 claims
Astellas Pharma US IncMyrbetriq$47$4,90111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Wilmington

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →